Skip to main content
. 2017 Oct 26;12(10):e0187088. doi: 10.1371/journal.pone.0187088

Fig 3.

Fig 3

Patient distributions in the training (n = 103) (A) and validation (n = 45) (B) cohort. Immune dysfunction score and 28-day mortality rate in the training (C) and validation (D) cohort.